Today’s post is an ICYMI and update on some reporting from the @moneystuff.bsky.social podcast. Two topics: Investment firms seeking to profit off the government’s obligations to reimburse those who paid tariffs and Novo Nordisk’s attempt to acquire Metsera or at least prevent Pfizer from doing so.

#law #contracts #tariffs #WallStreet #NovoNordisk #Pfizer #Ozempic #Metsera

https://www.contractsprofblog.com/2025/11/a-couple-tidbits-from-the-world-of-business/

Can co-formulated amylin + GLP-1 deliver persistence without the side-effect drop-offs? Our deep dive on #Pfizer × #Metsera and the next readouts to watch.
🔗
biotech.industryexaminer.com/pfizer-metsera-amylin-glp1-monthly-obesity-tolerability/

#biotech #GLP1

Metsera shares soared nearly 60% after announcing a potential $7.3 billion acquisition by Pfizer, reflecting strong investor optimism in the obesity drug sector.
#YonhapInfomax #Metsera #Pfizer #Acquisition #ObesityTreatment #SharePriceSurge #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82892
Metsera Shares Surge 60% on News of Pfizer Acquisition

Metsera shares soared nearly 60% after announcing a potential $7.3 billion acquisition by Pfizer, reflecting strong investor optimism in the obesity drug sector.

Yonhap Infomax
D&D Pharmatech shares hit the daily upper limit after news that partner Metsera is in talks for a $7.3 billion acquisition by Pfizer, boosting market optimism.
#YonhapInfomax #DDPharmatech #Metsera #Pfizer #ObesityTreatment #MASHMarketGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82823
D&D Pharmatech Shares Surge to Daily Limit on Expectations of Partner Metsera’s Acquisition

D&D Pharmatech shares hit the daily upper limit after news that partner Metsera is in talks for a $7.3 billion acquisition by Pfizer, boosting market optimism.

Yonhap Infomax